LisaLancasterMD
Pulmonology • Nashville, TNCritical Care Medicine, Interstitial Lung Diseases, Sleep Medicine
Professor, Medicine, Vanderbilt University School of Medicine
Dr. Lancaster is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-322-3000
Summary
- Dr. Lisa Lancaster is a pulmonologist in Nashville, TN and is affiliated with Vanderbilt University Medical Center. She received her medical degree from Medical College of Georgia School of Medicine and has been in practice 24 years. She specializes in pulmonary medicine, interstitial lung disease, idiopathic pulmonary fibrosis, and sleep medicine and is experienced in transplant pulmonology, cystic fibrosis, and ILD clinical trials.
Education & Training
Vanderbilt University Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 1999
University of Tennessee (Nashville)Residency, Internal Medicine, 1993 - 1996
Medical College of Georgia at Augusta UniversityClass of 1993
Certifications & Licensure
TN State Medical License 1996 - 2025
AL State Medical License 2020 - 2020- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Nashville Lifestyles Magazine Castle Connolly, 2008, 2011, 2013-2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Top MD Consumers Checkbook
Clinical Trials
- STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2012 Jul 16
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
- Join now to see all
Publications & Presentations
PubMed
- Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled Trial.Steven D Nathan, Natasa Rajicic, Rosemarie Dudenhofer, Rahat Hussain, Rahul Argula
Annals of the American Thoracic Society. 2024-12-01 - 3 citationsPhase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis.Waldo L L D Mattos, Nasreen Khalil, Lisa G Spencer, Francesco Bonella, Rodney J Folz
American Journal of Respiratory and Critical Care Medicine. 2024-08-15 - 1 citationsBexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.Lisa Lancaster, Vincent Cottin, Murali Ramaswamy, Wim A Wuyts, R Gisli Jenkins
American Journal of Respiratory and Critical Care Medicine. 2024-08-15
Press Mentions
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast Was Well Tolerated at 320 Mg with Durable Improvement Shown in FVC and Across Multiple MeasuresApril 30th, 2023- Highest Dose Bexotegrast Found to Improve Lung Function in IPFJanuary 31st, 2023
- Envisia Test May Help Identify ILD Patients with Progressing DiseaseOctober 21st, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
